on Biophytis (EPA:ALBPS)
Biophytis Expands AI Partnership with LynxKite for Longevity Drug Discovery
Biophytis, a biotech company in Paris, has announced an expansion of its alliance with LynxKite Technologies. This collaboration focuses on AI-driven drug discovery targeting age-related diseases. A notable project, MASSIVE, aims to identify Mas receptor activator drugs for sarcopenia, a muscle disease linked to aging.
The partnership combines Biophytis' expertise in Mas receptor pharmacology with LynxKite's AI technologies. This alliance supports Singapore's RIE 2030 plan, aligning with global efforts to address diseases affecting the elderly. LynxKite's platform integrates NVIDIA tools and cloud services, enhancing computational methods for longevity research.
Key goals include modeling drug structures using AI, generating synthetic candidates, and testing Mas receptor activators. This collaboration underlines Biophytis' commitment to innovative therapies, further reinforcing its drug discovery platform for longevity therapeutics.
R. E.
Copyright © 2026 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Biophytis news